Roivant Sciences Ltd.

Insider Reports History

Reporting-owner location: London
Latest reporting-owner signature: /s/ Keyur Parekh, as Authorized Signatory
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Roivant Sciences Ltd.

Form 4 holding Director, 10%+ Owner

Immunovant, Inc.

Security class: Common Stock, $0.0001 par value per share
Shares / value: 113,317,007
Estimated value: $2,379,657,147
Report date: 12 Dec 2025
Price: $21.00
Ownership: Direct

Form 4 holding 10%+ Owner

Arbutus Biopharma Corp

Security class: Common shares, without par value
Shares / value: 38,847,462
Estimated value
Report date: 18 Oct 2021
Price
Ownership: Direct

Form 4 holding 10%+ Owner

Arbutus Biopharma Corp

Security class: Series A participating convertible preferred shares
Shares / value: 0
Estimated value
Report date: 18 Oct 2021
Price
Ownership: Direct
Underlying class: Common shares
Underlying amount

Insider Reports Filed by Roivant Sciences Ltd.

4 IMVT

Immunovant, Inc.

Report period: 12 Dec 2025
Transactions: 1
Transaction value: +$349,999,986
Accepted by SEC: 12 Dec 2025, 17:17
Role: Director, 10%+ Owner
Next action: Open filing details

4 IMVT

Immunovant, Inc.

Report period: 13 Jan 2025
Transactions: 1
Transaction value: +$336,900,200
Accepted by SEC: 15 Jan 2025, 16:36
Role: Director, 10%+ Owner
Next action: Open filing details

4 IMVT

Immunovant, Inc.

Report period: 02 Oct 2023
Transactions: 2
Transaction value: +$228,000,000
Accepted by SEC: 04 Oct 2023, 17:15
Role: Director, 10%+ Owner
Next action: Open filing details

4 IMVT

Immunovant, Inc.

Report period: 06 Oct 2022
Transactions: 1
Transaction value: +$2,500,002
Accepted by SEC: 07 Oct 2022, 16:32
Role: 10%+ Owner
Next action: Open filing details

4 ABUS

Arbutus Biopharma Corp

Report period: 18 Oct 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 20 Oct 2021, 17:14
Role: 10%+ Owner
Next action: Open filing details

4 IMVT

Immunovant, Inc.

Report period: 02 Aug 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 02 Aug 2021, 21:46
Role: 10%+ Owner
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .